{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:44:05Z","timestamp":1787024645700,"version":"build-2736575974"},"reference-count":58,"publisher":"Bentham Science Publishers Ltd.","issue":"12","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract:<\/jats:title>\n                    <jats:p>Spinal muscular atrophy (SMA) is a hereditary disorder affecting neurons and\nmuscles, resulting in muscle weakness and atrophy. Most SMA cases are diagnosed during\ninfancy or early childhood, the most common inherited cause of infant mortality without\ntreatment. Still, SMA might appear at older ages with milder symptoms. SMA patients\ndemonstrate progressive muscle waste, movement problems, tremors, dysphagia,\nbone and joint deformations, and breathing difficulties. The mammalian target of rapamycin\n(mTOR), the mechanistic target of rapamycin, is a member of the phosphatidylinositol\n3-kinase-related kinase family of protein kinases encoded by the mTOR gene in\nhumans. The mTOR phosphorylation, deregulation, and autophagy have shown dissimilarity\namongst SMA cell types. Therefore, exploring the underlying molecular process in\nSMA therapy could provide novel insights and pave the way for finding new treatment\noptions. This paper provides new insight into the possible modulatory effect of mTOR\/\nautophagy in SMA management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0929867330666230213114909","type":"journal-article","created":{"date-parts":[[2023,2,15]],"date-time":"2023-02-15T00:54:31Z","timestamp":1676422471000},"page":"1512-1522","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Spinal Muscular Atrophy Treatment: The MTOR Regulatory\nIntervention"],"prefix":"10.2174","volume":"31","author":[{"given":"Naser-Aldin","family":"Lashgari","sequence":"first","affiliation":[{"name":"Department of Toxicology &amp; Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad\nUniversity, Tehran, Iran"},{"name":"GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research\nNetwork (USERN), Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin Momeni","family":"Roudsari","sequence":"additional","affiliation":[{"name":"Department of Toxicology &amp; Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad\nUniversity, Tehran, Iran"},{"name":"GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research\nNetwork (USERN), Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shayan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Medicine, Tehran University\nof Medical Sciences, Tehran, Iran"},{"name":"Experimental Medicine Research Center, Tehran University of Medical\nSciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf","family":"Eshraghi","sequence":"additional","affiliation":[{"name":"Department of Toxicology &amp; Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad\nUniversity, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeideh","family":"Momtaz","sequence":"additional","affiliation":[{"name":"GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research\nNetwork (USERN), Tehran, Iran"},{"name":"Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR,\nKaraj, Iran"},{"name":"Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC),\nThe Institute of Pharmaceutical Sciences (TIPS), and Faculty of Pharmacy, Tehran University of Medical\nSciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannaz","family":"Jamialahmadi","sequence":"additional","affiliation":[{"name":"Surgical Oncology Research Center, Mashhad University of Medical Sciences,\nMashhad, Iran"},{"name":"Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Abdolghaffari","sequence":"additional","affiliation":[{"name":"Department of Toxicology &amp; Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad\nUniversity, Tehran, Iran"},{"name":"GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research\nNetwork (USERN), Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[{"name":"Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad,\nIran"},{"name":"Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical\nSciences, Mashhad, Iran"},{"name":"School of Medicine, The University of Western Australia, Perth, Australia"},{"name":"Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"Verhaart I.E.C.","year":"2017","unstructured":"Verhaart I.E.C.; Robertson A.; Wilson I.J.; Aartsma-Rus A.; Cameron S.; Jones C.C.; Cook S.F.; Lochm&#xFC;ller H.; Prevalence, incidence and carrier frequency of 5q\u2013linked spinal muscular atrophy \u2013 a literature review. Orphanet J Rare Dis  2017,12(1),124","journal-title":"Orphanet J Rare Dis"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2011.09.001","volume":"46","author":"Markowitz J.A.","year":"2012","unstructured":"Markowitz J.A.; Singh P.; Darras B.T.; Spinal muscular atrophy: A clinical and research update. Pediatr Neurol  2012,46(1),1-12","journal-title":"Pediatr Neurol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/14656566.2019.1704732","volume":"21","author":"Ramdas S.","year":"2020","unstructured":"Ramdas S.; Servais L.; New treatments in spinal muscular atrophy: An overview of currently available data. Expert Opin Pharmacother  2020,21(3),307-315","journal-title":"Expert Opin Pharmacother"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"Schorling D.C.","year":"2020","unstructured":"Schorling D.C.; Pechmann A.; Kirschner J.; Advances in treatment of spinal muscular atrophy\u2013new phenotypes, new challenges, new implications for care. J Neuromuscul Dis  2020,7(1),1-13","journal-title":"J Neuromuscul Dis"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1021\/acsptsci.1c00230","volume":"5","author":"Wang T.","year":"2022","unstructured":"Wang T.; Long K.; Zhou Y.; Jiang X.; Liu J.; Fong J.H.C.; Wong A.S.L.; Ng W.L.; Wang W.; Optochemical control of mTOR signaling and mTOR-dependent autophagy. ACS Pharmacol Transl Sci  2022,5(3),149-155","journal-title":"ACS Pharmacol Transl Sci"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/jcmm.13450","volume":"22","author":"Magri F.","year":"2018","unstructured":"Magri F.; Vanoli F.; Corti S.; miRNA in spinal muscular atrophy pathogenesis and therapy. J Cell Mol Med  2018,22(2),755-767","journal-title":"J Cell Mol Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1172\/JCI95231","volume":"128","author":"Rodriguez-Muela N.","year":"2018","unstructured":"Rodriguez-Muela N.; Parkhitko A.; Grass T.; Gibbs R.M.; Norabuena E.M.; Perrimon N.; Singh R.; Rubin L.L.; Blocking p62-dependent SMN degradation ameliorates spinal muscular atrophy disease phenotypes. J Clin Invest  2018,128(7),3008-3023","journal-title":"J Clin Invest"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/DDDT.S188968","volume":"13","author":"Wang Y.","year":"2018","unstructured":"Wang Y.; Shao Y.; Gao Y.; Wan G.; Wan D.; Zhu H.; Qiu Y.; Ye X.; Catalpol prevents denervated muscular atrophy related to the inhibition of autophagy and reduces BAX\/BCL2 ratio via mTOR pathway. Drug Des Devel Ther  2018,13,243-253","journal-title":"Drug Des Devel Ther"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/B978-0-12-803685-3.00012-4","author":"Wirth B.","year":"2017","unstructured":"Wirth B.; Mendoza-Ferreira N.; Torres-Benito L.;  Spinal muscular atrophy disease modifiers Spinal muscular atrophy  2017,191-210","journal-title":"Spinal muscular atrophy disease modifiers Spinal muscular atrophy"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1242\/jcs.051011","volume":"122","author":"Laplante M","year":"2009","unstructured":"Laplante M; Sabatini DM; mTOR signaling at a glance. J Cell Sci  2009,122(20),3589-3594","journal-title":"J Cell Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nri3901","volume":"15","author":"Weichhart T","year":"2015","unstructured":"Weichhart T; Hengstschl&#xE4;ger M; Linke M; Regulation of innate immune cell function by mTOR. Nature Reviews Immunology  2015,15(10),599-614","journal-title":"Nature Reviews Immunology"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5497\/wjp.v11.i1.1","volume":"11","author":"Lashgari N.A.","year":"2022","unstructured":"Lashgari N.A.; Roudsari N.M.; Momtaz S.; Abdolghaffari A.H.; Mammalian target of rapamycin; novel insight for management of inflammatory bowel diseases. World J Pharmacol  2022,11(1),1-5","journal-title":"World J Pharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.2174\/1875533XMTA2jMzE32","volume":"28","author":"Lashgari N.A.","year":"2021","unstructured":"Lashgari N.A.; Roudsari N.M.; Momtaz S.; Ghanaatian N.; Kohansal P.; Farzaei M.H.; Afshari K.; Sahebkar A.; Abdolghaffari A.H.; Targeting mammalian target of rapamycin: Prospects for the treatment of inflammatory bowel diseases. Curr Med Chem  2021,28(8),1605-1624","journal-title":"Curr Med Chem"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.molcel.2010.05.017","volume":"38","author":"Yip CK","year":"2010","unstructured":"Yip CK; Murata K; Walz T; Sabatini DM; Kang SA; Structure of the human mTOR complex I and its implications for rapamycin inhibition. Molecular Cell  2010,38(5),768-774","journal-title":"Molecular Cell"},{"key":"ref=15","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc1251","volume":"6","author":"Scaiola A.","year":"2020","unstructured":"Scaiola A.; Mangia F.; Imseng S.; Boehringer D.; Berneiser K.; Shimobayashi M; The 3.2-&#xC5; resolution structure of human mTORC2. Science Advances  2020,6(45)","journal-title":"Science Advances"},{"key":"ref=16","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-019-0806-3","volume":"7","author":"Rehorst WA","year":"2019","unstructured":"Rehorst WA; Thelen MP; Nolte H; T&#xFC;rk C; Cirak S; Peterson JM; Muscle regulates mTOR dependent axonal local translation in motor neurons via CTRP3 secretion: Implications for a neuromuscular disorder, spinal muscular atrophy. Acta Neuropathol Commun  2019,7(1)","journal-title":"Acta Neuropathol Commun"},{"key":"ref=17","volume":"57","year":"2015","unstructured":"Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: A. D - 101572336  2015,57"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.pharmthera.2013.03.005","volume":"138","author":"Ferri N.","year":"2013","unstructured":"Ferri N.; Siegl P.; Corsini A.; Herrmann J.; Lerman A.; Benghozi R.; Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity. Pharmacol Ther  2013,138(3),470-484","journal-title":"Pharmacol Ther"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jnutbio.2016.12.011","volume":"41","author":"Granato M.","year":"2017","unstructured":"Granato M.; Rizzello C.; Gilardini Montani M.S.; Cuomo L.; Vitillo M.; Santarelli R.; Gonnella R.; D\u2019Orazi G.; Faggioni A.; Cirone M.; Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K\/AKT\/mTOR and STAT3 signaling pathways. J Nutr Biochem  2017,41,124-136","journal-title":"J Nutr Biochem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1111\/j.1600-6143.2009.02832.x","volume":"9","author":"S&#xE4;emann M.D.","year":"2009","unstructured":"S&#xE4;emann M.D.; Haidinger M.; Hecking M.; H&#xF6;rl W.H.; Weichhart T.; The multifunctional role of mTOR in innate immunity: Implications for transplant immunity. Am J Transplant  2009,9(12),2655-2661","journal-title":"Am J Transplant"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nri2457","volume":"8","author":"Allan S.","year":"2008","unstructured":"Allan S.; Seeing mTOR in a new light. Nature Reviews Immunology  2008,8(12),904","journal-title":"Nature Reviews Immunology"},{"key":"ref=22","author":"Arumugam S.","year":"2017","unstructured":"Arumugam S.; A study on the role of nf-kb signaling pathway members in regulating survival motor neuron protein level and in the pathogenesis of spinal muscular atrophy: Universitat de lleida  2017"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.3390\/antiox11091686","volume":"11","author":"Ji Y.","year":"2022","unstructured":"Ji Y.; Li M.; Chang M.; Liu R.; Qiu J.; Wang K.; Deng C.; Shen Y.; Zhu J.; Wang W.; Xu L.; Sun H.; Inflammation: Roles in skeletal muscle atrophy. Antioxidants  2022,11(9),1686","journal-title":"Antioxidants"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.immuni.2008.08.012","volume":"29","author":"Weichhart T.","year":"2008","unstructured":"Weichhart T.; Costantino G.; Poglitsch M.; Rosner M.; Zeyda M.; Stuhlmeier K.M.; The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity  2008,29(4),565-577","journal-title":"Immunity"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"7S3","DOI":"10.1016\/S0929-693X(20)30269-4","volume":"27","author":"Lefebvre S.","year":"2020","unstructured":"Lefebvre S.; Sarret C.; Pathogenesis and therapeutic targets in spinal muscular atrophy (SMA). Archives de P&#xE9;diatrie  2020,27(7),7S3-7S8","journal-title":"Archives de P&#xE9;diatrie"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/archneurol.2011.74","volume":"68","author":"Kolb S.J.","year":"2011","unstructured":"Kolb S.J.; Kissel J.T.; Spinal muscular atrophy: A timely review. Arch Neurol  2011,68(8),979-984","journal-title":"Arch Neurol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fneur.2020.00045","volume":"11","author":"Hensel N.","year":"2020","unstructured":"Hensel N.; Kubinski S.; Claus P.; The need for SMN-independent treatments of spinal muscular atrophy (SMA) to complement SMN-enhancing drugs. Front Neurol  2020,11,45","journal-title":"Front Neurol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/acn3.423","volume":"4","author":"Deguise M.-O.","year":"2017","unstructured":"Deguise M.-O.; Kothary R.; New insights into SMA pathogenesis: Immune dysfunction and neuroinflammation. Ann Clin Transl Neurol  2017,4(7),522-530","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=29","author":"Mena T.","year":"2018","unstructured":"Mena T.; Spinal Muscular Atrophy (SMA) Nemours KidsHealth  Available From:  https:\/\/kidshealth.org\/en\/parents\/sma.html#:~:text=Type%20I%2C%20sometimes%20called%20infantile,7%20and%2018%20months%20old2018"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1242\/dmm.030148","volume":"10","author":"Bowerman M.","year":"2017","unstructured":"Bowerman M.; Becker C.G.; Y&#xE1;&#xF1;ez-Mu&#xF1;oz R.J.; Ning K.; Wood M.J.A.; Gillingwater T.H.; Talbot K.; Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis Model Mech  2017,10(8),943-954","journal-title":"Dis Model Mech"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnen\/64.3.215","volume":"64","author":"Soler-Botija C.","year":"2005","unstructured":"Soler-Botija C.; Cusc&#xF3; I.; Caselles L.; L&#xF3;pez E.; Baiget M.; Tizzano E.F.; Implication of fetal SMN2 expression in type I SMA pathogenesis: Protection or pathological gain of function? J Neuropathol Exp Neurol  2005,64(3),215-223","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3390\/cells11030417","volume":"11","author":"Aslesh T.","year":"2022","unstructured":"Aslesh T.; Yokota T.; Restoring SMN expression: An overview of the therapeutic developments for the treatment of spinal muscular atrophy. Cells  2022,11(3),417","journal-title":"Cells"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/ana.26299","volume":"91","author":"Yeo C.J.J.","year":"2022","unstructured":"Yeo C.J.J.; Simmons Z.; De Vivo D.C.; Darras B.T.; Ethical perspectives on treatment options with spinal muscular atrophy patients. Ann Neurol  2022,91(3),305-316","journal-title":"Ann Neurol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3390\/biology11060894","volume":"11","author":"L&#xF3;pez-Cort&#xE9;s A.","year":"2022","unstructured":"L&#xF3;pez-Cort&#xE9;s A.; Echeverr&#xED;a-Garc&#xE9;s G.; Ramos-Medina M.J.; Molecular pathogenesis and new therapeutic dimensions for spinal muscular atrophy. Biology (Basel)  2022,11(6),894","journal-title":"Biology (Basel)"},{"key":"ref=35","first-page":"1","author":"Reilly A.","year":"2022","unstructured":"Reilly A.; Chehade L.; Kothary R.; Curing SMA: Are we there yet? Gene Ther  2022,1-10","journal-title":"Gene Ther"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/jgc4.1549","volume":"31","author":"Zettler B.","year":"2022","unstructured":"Zettler B.; Estrella E.; Liaquat K.; Lichten L.; Evolving approaches to prenatal genetic counseling for Spinal Muscular Atrophy in the new treatment era. J Genet Couns  2022,31(3),803-814","journal-title":"J Genet Couns"},{"key":"ref=37","author":"Brakemeier S","year":"2022","unstructured":"Brakemeier S; Stolte B; Kleinschnitz C; Hagenacker T.; Treatment of adult spinal muscular atrophy: Overview and recent developments. Curr Pharma Design  2022","journal-title":"Curr Pharma Design"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"570270","DOI":"10.3389\/fphys.2020.570270","volume":"11","author":"Guo B.","year":"2020","unstructured":"Guo B.; Zhuang T.; Xu F.; Lin X.; Li F.; Shan S.K.; Wu F.; Zhong J.Y.; Wang Y.; Zheng M.H.; Xu Q.S.; Ehsan U.M.H.; Yuan L.Q.; New insights into implications of CTRP3 in obesity, metabolic dysfunction, and cardiovascular diseases: Potential of therapeutic interventions. Front Physiol  2020,11,570270","journal-title":"Front Physiol"},{"key":"ref=39","author":"Rehorst WA","year":"2019","unstructured":"Rehorst WA; Muscle-secreted factors in spinal muscular atrophy: CTRP3 at the interface of muscle and neuron.  2019"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"166063","DOI":"10.1016\/j.bbadis.2020.166063","volume":"1867","author":"Singh N.N.","year":"2021","unstructured":"Singh N.N.; Hoffman S.; Reddi P.P.; Singh R.N.; Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes. Biochim Biophys Acta Mol Basis Dis  2021,1867(4),166063","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.mcn.2014.06.006","volume":"61","author":"Custer S.K.","year":"2014","unstructured":"Custer S.K.; Androphy E.J.; Autophagy dysregulation in cell culture and animals models of spinal muscular atrophy. Mol Cell Neurosci  2014,61,133-140","journal-title":"Mol Cell Neurosci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1038\/s41419-017-0086-4","volume":"8","author":"Piras A.","year":"2017","unstructured":"Piras A.; Schiaffino L.; Boido M.; Valsecchi V.; Guglielmotto M.; De Amicis E.; Puyal J.; Garcera A.; Tamagno E.; Soler R.M.; Vercelli A.; Inhibition of autophagy delays motoneuron degeneration and extends lifespan in a mouse model of spinal muscular atrophy. Cell Death Dis  2017,8(12),3223","journal-title":"Cell Death Dis"},{"key":"ref=43","doi-asserted-by":"crossref","DOI":"10.1186\/s40478-021-01223-5","volume":"9","author":"Sansa A.","year":"2021","unstructured":"Sansa A.; Hidalgo I.; Miralles M.P.; de la Fuente S.; Perez-Garcia M.J.; Munell F.; Spinal Muscular Atrophy autophagy profile is tissue-dependent: Differential regulation between muscle and motoneurons. Acta Neuropathol Commun  2021,9(1)","journal-title":"Acta Neuropathol Commun"},{"key":"ref=44","author":"Zhang Q.","year":"2015","unstructured":"Zhang Q.; Role of mTOR kinase activity in skeletal muscle integrity and physiology: Ecole normale sup&#xE9;rieure de lyon-ENS LYON. East China Normal University  2015","journal-title":"East China Normal University"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"ra18","DOI":"10.1126\/scisignal.2004809","volume":"7","author":"Tang H.","year":"2014","unstructured":"Tang H.; Inoki K.; Lee M.; Wright E.; Khuong A.; Khuong A.; Sugiarto S.; Garner M.; Paik J.; DePinho R.A.; Goldman D.; Guan K.L.; Shrager J.B.; mTORC1 promotes denervation-induced muscle atrophy through a mechanism involving the activation of FoxO and E3 ubiquitin ligases. Sci Signal  2014,7(314),ra18","journal-title":"Sci Signal"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3390\/nu14091859","volume":"14","author":"Wang P.","year":"2022","unstructured":"Wang P.; Kang S.Y.; Kim S.J.; Park Y.K.; Jung H.W.; Monotropein improves dexamethasone-induced muscle atrophy via the AKT\/mTOR\/FOXO3a signaling pathways. Nutrients  2022,14(9),1859","journal-title":"Nutrients"},{"key":"ref=47","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-7-14","volume":"7","author":"Millino C.","year":"2009","unstructured":"Millino C.; Fanin M.; Vettori A.; Laveder P.; Mostacciuolo M.L.; Angelini C.; Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy. BMC Med  2009,7(1)","journal-title":"BMC Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/SHK.0000000000001860","volume":"57","author":"Yin D.","year":"2022","unstructured":"Yin D.; Lin D.; Xie Y.; Gong A.; Jiang P.; Wu J.; Neuregulin-1&#x3B2; alleviates sepsis-induced skeletal muscle atrophy by inhibiting autophagy via akt\/mtor signaling pathway in rats. Shock: Injury, Inflammation, and Sepsis. Shock  2022,57(3),397-407","journal-title":"Shock"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s41418-021-00912-x","volume":"29","author":"Valionyte E.","year":"2022","unstructured":"Valionyte E.; Yang Y.; Griffiths S.A.; Bone A.T.; Barrow E.R.; Sharma V.; Lu B.; Luo S.; The caspase-6\u2013p62 axis modulates p62 droplets based autophagy in a dominant-negative manner. Cell Death Differ  2022,29(6),1211-1227","journal-title":"Cell Death Differ"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1471-2377-11-36","volume":"11","author":"Darbar I.A.","year":"2011","unstructured":"Darbar I.A.; Plaggert P.G.; Resende M.B.D.; Zanoteli E.; Reed U.C.; Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. BMC Neurol  2011,11(1),36","journal-title":"BMC Neurol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/gt.2017.46","volume":"24","author":"Jablonka S.","year":"2017","unstructured":"Jablonka S.; Sendtner M.; Developmental regulation of SMN expression: Pathophysiological implications and perspectives for therapy development in spinal muscular atrophy. Gene Ther  2017,24(9),506-513","journal-title":"Gene Ther"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00401-016-1550-4","volume":"132","author":"Rocchi A.","year":"2016","unstructured":"Rocchi A.; Milioto C.; Parodi S.; Armirotti A.; Borgia D.; Pellegrini M.; Urciuolo A.; Molon S.; Morbidoni V.; Marabita M.; Romanello V.; Gatto P.; Blaauw B.; Bonaldo P.; Sambataro F.; Robins D.M.; Lieberman A.P.; Sorar&#xF9; G.; Vergani L.; Sandri M.; Pennuto M.; Glycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat diet. Acta Neuropathol  2016,132(1),127-144","journal-title":"Acta Neuropathol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ebiom.2018.04.024","volume":"31","author":"Walter L.M.","year":"2018","unstructured":"Walter L.M.; Deguise M.O.; Meijboom K.E.; Betts C.A.; Ahlskog N.; van Westering T.L.E.; Hazell G.; McFall E.; Kordala A.; Hammond S.M.; Abendroth F.; Murray L.M.; Shorrock H.K.; Prosdocimo D.A.; Haldar S.M.; Jain M.K.; Gillingwater T.H.; Claus P.; Kothary R.; Wood M.J.A.; Bowerman M.; Interventions targeting glucocorticoid-kr&#xFC;ppel-like factor 15-branched-chain amino acid signaling improve disease phenotypes in spinal muscular atrophy mice. EBioMedicine  2018,31,226-242","journal-title":"EBioMedicine"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.phrs.2016.05.023","volume":"111","author":"Tseng Y.T.","year":"2016","unstructured":"Tseng Y.T.; Chen C.S.; Jong Y.J.; Chang F.R.; Lo Y.C.; Loganin possesses neuroprotective properties, restores SMN protein and activates protein synthesis positive regulator Akt\/mTOR in experimental models of spinal muscular atrophy. Pharmacol Res  2016,111,58-75","journal-title":"Pharmacol Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"6318","DOI":"10.1093\/hmg\/ddu350","volume":"23","author":"Kye M.J.","year":"2014","unstructured":"Kye M.J.; Niederst E.D.; Wertz M.H.; Gon&#xE7;alves I.C.G.; Akten B.; Dover K.Z.; Peters M.; Riessland M.; Neveu P.; Wirth B.; Kosik K.S.; Sardi S.P.; Monani U.R.; Passini M.A.; Sahin M.; SMN regulates axonal local translation via miR-183\/mTOR pathway. Hum Mol Genet  2014,23(23),6318-6331","journal-title":"Hum Mol Genet"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1093\/hmg\/ddq226","volume":"19","author":"Ning K.","year":"2010","unstructured":"Ning K.; Drepper C.; Valori C.F.; Ahsan M.; Wyles M.; Higginbottom A.; Herrmann T.; Shaw P.; Azzouz M.; Sendtner M.; PTEN depletion rescues axonal growth defect and improves survival in SMN-deficient motor neurons. Hum Mol Genet  2010,19(16),3159-3168","journal-title":"Hum Mol Genet"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.3390\/cells10113015","volume":"10","author":"Gabanella F.","year":"2021","unstructured":"Gabanella F.; Barbato C.; Fiore M.; Petrella C.; de Vincentiis M.; Greco A.; Minni A.; Corbi N.; Passananti C.; Di Certo M.G.; Fine-tuning of mTOR mRNA and nucleolin complexes by SMN. Cells  2021,10(11),3015","journal-title":"Cells"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/jor.22096","volume":"30","author":"Liu X.","year":"2012","unstructured":"Liu X.; Joshi S.K.; Samagh S.P.; Dang Y.X.; Laron D.; Lovett D.H.; Bodine S.C.; Kim H.T.; Feeley B.T.; Evaluation of Akt\/mTOR activity in muscle atrophy after rotator cuff tears in a rat model. J Orthop Res  2012,30(9),1440-1446","journal-title":"J Orthop Res"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230213114909","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/213618\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230213114909","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T13:10:20Z","timestamp":1713359420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/213618\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666230213114909","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-07-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}